Company / Current Assets
Larimar Therapeutics, Inc. Current Assets History
FY2014-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$71.5M
FY2019
5-year range
$71.5M / $188.1M
FY2015-FY2019
Trend
-41.1%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has fluctuated over the past 6 years, ranging from $72M in FY2019 to $188M in FY2015.
Based on SEC 10-K filings.
$72M in FY2019 with a 5-year CAGR of -9.4%.
Declined from $105M to $72M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -18.3%
- 5-Year CAGR
- -9.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -9.4%, indicating a declining trend.
- In FY2019, current assets decreased 41.1% year-over-year.
- Peak current assets was recorded in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -4.64 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $71.5M | -41.1% |
| FY2018 | $121.3M | +15.6% |
| FY2017 | $104.9M | -19.8% |
| FY2016 | $130.9M | -30.4% |
| FY2015 | $188.1M | +60.5% |
| FY2014 | $117.2M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026